An interventional study of Intense Pulsed Light (IPL) - Lumecca and Rosacure anti-redness dermocosmetic regimen in Rosacea, sponsored by Medical University of Silesia. Completed at 1 site in Poland. Open to participants aged 20 Years to 57 Years. Per ClinicalTrials.gov, last updated 2026-07-27.
Sponsored by Medical University of Silesia · Not applicable, Interventional, and Treatment
This study compares three approaches to treating persistent facial redness in adults with erythematotelangiectatic rosacea: intense pulsed light (IPL) treatment alone, a professional anti-redness dermocosmetic skincare regimen alone, and the combination of both. The main question the study aims to answer is which of these three strategies is more effective at reducing facial redness, using both clinician grading and objective skin-imaging tools that measure redness and skin texture before and after treatment.
This was a prospective, single-center, three-arm comparative study conducted in an outpatient setting, with 60 adult patients with a dermatologist-confirmed diagnosis of erythematotelangiectatic rosacea allocated to one of three parallel treatment groups (20 patients per group). No randomization or blinding was performed.
Group 1 (IPL) received three intense pulsed light treatments with the Lumecca applicator (InMode; 515-1200 nm) at 21-day intervals, with fluence individually titrated to skin response; broad-spectrum SPF 50+ sunscreen was applied after each session, and daily photoprotection was mandatory.
Group 2 (dermocosmetic) received four professional in-office anti-redness treatments using the Rosacure Professional system (Synchroline/Cantabria Labs) at 7-day intervals - gentle cleansing, application of Rosacure Professional Serum Booster, and a leave-on regenerating gel mask - together with a standardized 12-week home-care regimen (twice-daily gentle cleanser, Rosacure Intensive SPF 30 in the morning, Rosacure Fast in the evening, and a leave-on mask twice weekly).
Group 3 (combination) received the same three IPL treatments as Group 1, immediately followed within the same session by the professional Rosacure protocol, at 21-day intervals, together with the same home-care regimen used in Group 2.
Facial redness was assessed using objective imaging (Antera 3D chromophore mapping and Gray-Level Co-occurrence Matrix texture analysis) and by clinician grading, at baseline, 2 weeks after the treatment series, and 8 weeks after the treatment series.
233 studies on the registry are indexed under Rosacea; 23 are open to participants now.
This study's enrollment of 60 is close to the median of 61 across 200 interventional studies indexed under Rosacea.
Browse Rosacea studies →Medical University of Silesia is the lead sponsor of 115 studies on the registry; 26 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Three intense pulsed light (IPL) treatments using the Lumecca applicator (InMode; 515-1200 nm) at 21-day intervals. Fluence was individually titrated to skin response and increased across sessions. Broad-spectrum sunscreen SPF 50+ was applied after each session, and daily photoprotection was mandatory.
Device: Intense Pulsed Light (IPL) - Lumecca
Four professional in-office anti-redness treatments using the Rosacure Professional system (Synchroline/Cantabria Labs) at 7-day intervals: gentle cleansing, application of Rosacure Professional Serum Booster (4-t-butylcyclohexanol, niacin amide, panthenol, sodium hyaluronate, polyglutamic acid), and a leave-on regenerating gel mask. Concurrently, a standardized 12-week home-care regimen: twice-daily gentle cleanser, Rosacure Intensive SPF 30 each morning, Rosacure Fast each evening, and a leave-on mask twice weekly.
Other: Rosacure anti-redness dermocosmetic regimen
Three IPL treatments identical to Arm 1 (Lumecca applicator, 515-1200 nm, 21-day intervals), immediately followed within the same session by the professional Rosacure protocol described in Arm 2, together with the same 12-week home-care regimen used in Arm 2.
Device: Intense Pulsed Light (IPL) - Lumecca · Other: Rosacure anti-redness dermocosmetic regimen
IPL treatment (515-1200 nm) delivered with the Lumecca applicator (InMode, Irvine, CA, USA), administered as three sessions at 21-day intervals with fluence individually titrated to skin response.
Professional in-office anti-redness regimen (Rosacure Professional system: gentle cleansing, Rosacure Professional Serum Booster, leave-on regenerating gel mask) plus a standardized 12-week home-care regimen (Rosacure Intensive SPF 30 mornings, Rosacure Fast evenings, leave-on mask twice weekly), manufactured by Synchroline/Cantabria Labs, Spain.
Antera 3D Erythema Index (Mean, Minimum, and Maximum)
Erythema quantified via the Antera 3D camera (Miravex, Dublin, Ireland), which reconstructs hemoglobin distribution from multidirectional, multispectral light reflectance and expresses erythema on a reproducible relative scale. For each patient and time point, three erythema indices - mean, minimum, and maximum - were extracted for the left and right cheek and averaged into a single value per index.
Time frame: Baseline, 2 weeks after the treatment series, and 8 weeks after the treatment series
GLCM Contrast
Gray-Level Co-occurrence Matrix (GLCM) texture parameter quantifying local brightness variation of the erythematous facial skin from cross-polarized photographs (8-bit grayscale, 256×256 co-occurrence matrix, horizontal offset θ=0°, distance d=1); higher values indicate a more irregular, mottled erythema. Left and right cheek values averaged per patient.
Time frame: Baseline, 2 weeks after the treatment series, and 8 weeks after the treatment series
GLCM Homogeneity
Gray-Level Co-occurrence Matrix (GLCM) texture parameter quantifying surface uniformity of the erythematous facial skin; higher values indicate more uniform erythema. Derived from the same cross-polarized photographs and co-occurrence matrix as GLCM contrast. Left and right cheek values averaged per patient.
Time frame: Baseline, 2 weeks after the treatment series, and 8 weeks after the treatment series
Clinician Erythema Assessment (CEA) Score
Semi-quantitative 5-point ordinal scale (0-4) graded by trained dermatologists, where 0 = no visible erythema and 4 = severe, intense redness; mean of scores from three independent raters.
Time frame: Baseline, 2 weeks after the treatment series, and 8 weeks after the treatment series
Plan to share: Yes — Individual participant data underlying the results of this study may be reported across one or more publications arising from this dataset. Data will be made available to qualified researchers upon reasonable request to the corresponding author.
Supporting information: Study protocol
Time frame: Available upon reasonable request from the corresponding author, beginning from the date of publication, with no specified end date.
Access criteria: Data will be made available to qualified researchers who submit a reasonable request to the corresponding author (Anna Deda, adeda@sum.edu.pl), for the purpose of methodologically sound reanalysis, subject to authors' approval.
Ran from Sep 2025 to primary completion in Apr 2026, 7 months.
Of 42 interventional studies with no phase under Rosacea, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 29. This study's 7 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Medical University of Silesia →